Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sex-Mismatched Allogeneic BMT for mCRPC
NCT02995330Phase 1Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Feb 2017
- Primary completion
- Jun 2021
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Prostate-specific Antigen Response at 6 months. Started Feb 2017; status: terminated.
02
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02995330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02995330.